PCAS Past Earnings Performance
Past criteria checks 2/6
PCAS's earnings have been declining at an average annual rate of -40.1%, while the Life Sciences industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 0.7% per year. PCAS's return on equity is 122.1%, and it has net margins of 3.8%.
Key information
-40.1%
Earnings growth rate
-40.2%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 0.7% |
| Return on equity | 122.1% |
| Net Margin | 3.8% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Statutory Earnings May Not Be The Best Way To Understand PCAS' (EPA:PCA) True Position
Sep 14
Is PCAS (EPA:PCA) A Risky Investment?
Dec 19Is PCAS (EPA:PCA) Weighed On By Its Debt Load?
May 24Did You Miss PCAS' (EPA:PCA) 48% Share Price Gain?
Mar 02PCAS'(EPA:PCA) Share Price Is Down 48% Over The Past Three Years.
Nov 25Revenue & Expenses BreakdownBeta
How PCAS makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 230 | 9 | 149 | 0 |
| 31 Mar 23 | 228 | -20 | 149 | 0 |
| 31 Dec 22 | 226 | -49 | 149 | 0 |
| 30 Sep 22 | 208 | -58 | 146 | 0 |
| 30 Jun 22 | 191 | -67 | 143 | 0 |
| 31 Mar 22 | 189 | -54 | 140 | 0 |
| 31 Dec 21 | 187 | -40 | 137 | 0 |
| 30 Sep 21 | 191 | -27 | 135 | 0 |
| 30 Jun 21 | 195 | -14 | 133 | 0 |
| 31 Mar 21 | 195 | -15 | 132 | 0 |
| 31 Dec 20 | 194 | -15 | 132 | 0 |
| 30 Sep 20 | 199 | -13 | 131 | 0 |
| 30 Jun 20 | 204 | -11 | 130 | 0 |
| 31 Mar 20 | 202 | -12 | 127 | 0 |
| 31 Dec 19 | 201 | -14 | 123 | 0 |
| 30 Sep 19 | 205 | -9 | 181 | 0 |
| 30 Jun 19 | 209 | -6 | 120 | 0 |
| 31 Mar 19 | 208 | -3 | 119 | 0 |
| 31 Dec 18 | 207 | 0 | 119 | 0 |
| 30 Sep 18 | 208 | -1 | 59 | 0 |
| 30 Jun 18 | 208 | 0 | 117 | 0 |
| 31 Mar 18 | 213 | 3 | 115 | 0 |
| 31 Dec 17 | 218 | 6 | 114 | 0 |
| 30 Sep 17 | 210 | 6 | 110 | 0 |
| 30 Jun 17 | 202 | 6 | 107 | 0 |
| 31 Mar 17 | 197 | 6 | 105 | 0 |
| 31 Dec 16 | 192 | 7 | 103 | 0 |
| 30 Sep 16 | 191 | 7 | 101 | 0 |
| 30 Jun 16 | 189 | 8 | 98 | 0 |
| 31 Mar 16 | 184 | 8 | 95 | 0 |
| 31 Dec 15 | 179 | 9 | 92 | 0 |
| 30 Sep 15 | 175 | 7 | 89 | 0 |
| 30 Jun 15 | 172 | 5 | 87 | 0 |
| 31 Mar 15 | 169 | 4 | 86 | 0 |
| 31 Dec 14 | 166 | 3 | 84 | 0 |
| 30 Sep 14 | 164 | 2 | 84 | 0 |
| 30 Jun 14 | 161 | 2 | 83 | 0 |
| 31 Mar 14 | 163 | 3 | 84 | 0 |
| 31 Dec 13 | 165 | 3 | 84 | 0 |
| 30 Jun 13 | 171 | 6 | 84 | 0 |
| 31 Mar 13 | 171 | 6 | 84 | 0 |
| 31 Dec 12 | 171 | 6 | 85 | 0 |
Quality Earnings: PCA has a high level of non-cash earnings.
Growing Profit Margin: PCA became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PCA has become profitable over the past 5 years, growing earnings by -40.1% per year.
Accelerating Growth: PCA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: PCA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (12.2%).
Return on Equity
High ROE: Whilst PCA's Return on Equity (122.06%) is outstanding, this metric is skewed due to their high level of debt.